LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

NanoKnife delivers a localized electrical pulse that can treat prostate cancer. Developed by medical device firm AngioDynamics and cleared by the Food and Drug Administration in December 2024, it ...

COLONIE - It was not even a year ago that the U.S. Food and Drug Administration granted AngioDynamics approval for its NanoKnife device to be used in prostate cancer treatment. Now, Time magazine says ...

Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors For the past 25 years, TIME’s Best ...

AngioDynamic’s NanoKnife device uses electrodes to kill cancer cells. The surgery for prostate cancer takes about an hour. COLONIE — Latham-based medical technology company AngioDynamics is ramping up ...

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance ...

Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention Approximately 40% of all ...